Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL) Meeting Abstract


Authors: Wolchok, J. D.; Kluger, H. M.; Callahan, M. K.; Postow, M. A.; Gordon, R. A.; Segal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Reed, K.; Burke, M. M.; Caldwell, A.; Kronenberg, S. A.; Agunwamba, B.; Feely, W.; Hong, Q.; Horak, C. E.; Korman, A. J.; Wigginton, J. M.; Gupta, A. K.; Sznol, M.
Abstract Title: Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL)
Meeting Title: 49th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 31
Issue: 15 Suppl.
Meeting Dates: 2013 May 31-Jun 4
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2013-05-20
Language: English
ACCESSION: WOS:000335419602713
PROVIDER: wos
Notes: Meeting Abstract: 9012^ -- Source: Wos
MSK Authors
  1. Jedd D Wolchok
    607 Wolchok
  2. Neil Howard Segal
    94 Segal
  3. Michael Andrew Postow
    175 Postow
  4. Naiyer A Rizvi
    150 Rizvi
  5. Ruth-Ann Roman
    26 Roman
  6. Alexander Meyer Lesokhin
    106 Lesokhin